You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View
See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.
Latest Type 2 Issues Articles
Popular Type 2 Issues Articles
Highly Recommended Type 2 Issues Articles
Send a link to this page to your friends and colleagues.
Since Novo Nordisk recently released an improved FlexPen in the United States, we thought we’d remind you of one of their values.
Type 2s who start their insulin with pens end up requiring much less medical care.
In a study funded by Novo Nordisk, researchers at Ohio State University have found that type 2s who move from oral meds to insulin would be wise to start with an insulin pen rather than a syringe.
It's not because the pens cost less than syringes and vials; in fact, they cost more. Rather, it's because type 2s who start their insulin with pens end up requiring much less medical care.
The researchers compared 1,162 type 2 Medicaid patients who began insulin therapy with syringes to 168 who began insulin by using Novo Nordisk insulin pens. They found that only about half the people in either group took their insulin properly, a fact that they attributed to the poor overall care that low-income people receive from Medicaid.
After summing up the costs of each group's emergency room visits, hospitalizations, and outpatient visits for diabetes-related conditions, the average cost for pen users was $14,857 a year. For syringe users, however, it was a whopping $31,764.
In another study, the same researchers compared more than 1,100 patients who were already on insulin when the study began. Half switched to a pen, and half stayed on injections. In that study, annual healthcare costs of pen users were more than for syringe users: $11,476 versus $10,755.
The researchers explained this contradictory finding by noting that pens are more expensive initially. They also hypothesized that pen users probably took their insulin as often as they were supposed to and that syringe users probably didn't, resulting in higher insulin costs for the pen users.
Source: EurekAlert; Clinical Therapeutics, August 2007
Categories: Diabetes, Diabetes, Insulin, Novo Nordisk, Pens, Syringes, Type 2 Issues
Diabetes Health is the essential resource for people living with diabetes- both newly diagnosed and experienced as well as the professionals who care for them. We provide balanced expert news and information on living healthfully with diabetes. Each issue includes cutting-edge editorial coverage of new products, research, treatment options, and meaningful lifestyle issues.

Comments
Add your comments about this article below. You can add comments as a registered user or anonymously. If you choose to post anonymously your comments will be sent to our moderator for approval before they appear on this page. If you choose to post as a registered user your comments will appear instantly.
When voicing your views via the comment feature, please respect the Diabetes Health community by refraining from comments that could be considered offensive to other people. Diabetes Health reserves the right to remove comments when necessary to maintain the cordial voice of the diabetes community.
For your privacy and protection, we ask that you do not include personal details such as address or telephone number in any comments posted.
Don't have your Diabetes Health Username? Register now and add your comments to all our content.
Register...
Register your Diabetes Health Username here.
Have Your Say...